Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dexcom (DXCM) Research & Development (2016 - 2025)

Dexcom (DXCM) has disclosed Research & Development for 16 consecutive years, with $148.2 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 6.24% to $148.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $599.1 million through Dec 2025, up 8.45% year-over-year, with the annual reading at $599.1 million for FY2025, 8.45% up from the prior year.
  • Research & Development for Q4 2025 was $148.2 million at Dexcom, down from $157.5 million in the prior quarter.
  • The five-year high for Research & Development was $157.5 million in Q3 2025, with the low at $109.4 million in Q1 2021.
  • Average Research & Development over 5 years is $132.9 million, with a median of $135.6 million recorded in 2022.
  • The sharpest move saw Research & Development skyrocketed 61.58% in 2021, then decreased 22.36% in 2022.
  • Over 5 years, Research & Development stood at $149.8 million in 2021, then decreased by 22.36% to $116.3 million in 2022, then increased by 17.02% to $136.1 million in 2023, then grew by 2.5% to $139.5 million in 2024, then grew by 6.24% to $148.2 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $148.2 million, $157.5 million, and $148.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.